Skip to main content
Log in

Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Clinicians recognize levodopa has a short-duration response (measured in hr) and a long-duration response (measured in days) in Parkinson's disease. In addition there is a diurnal pattern of motor function with better function in the morning. Previous pharmacokinetic-pharmacodynamic modeling has quantified only the short-duration response. We have developed a pharmacokinetic-pharmacodynamic model for the short- and long-duration responses to exogenous levodopa and the effects of residual endogenous levodopa synthesis in patients with Parkinson's disease. Thirteen previously untreated (de novo) patients with Parkinson's disease and twelve patients who had received levodopa orally for 9.7 ± 4.0 years (chronic) were investigated. A 2 hr IV infusion of levodopa with concomitant oral carbidopa was given on two occasions separated by 3 days with no levodopa in between. A two compartment pharmacokinetic model was used to fit plasma levodopa concentrations. A sigmoid Emax model was used to relate concentrations from endogenous and exogenous sources to tapping rate (a measure of motor response). A model incorporating three effect compartments (fast equilibration (half life, Teqf), slow equilibration (Teqs) and dopa synthesis (Teqd)), yielded the most descriptive model for levodopa pharmacokinetics and pharmacodynamics. Baseline tapping rate reflected endogenous levodopa synthesis and the long-duration response. Partial loss of the long-duration response during the 3 days without levodopa in the chronic group lowered baseline tapping (36 ± 7%, mean ± SEM) and increased maximum levodopa induced response above baseline (112 ± 31%). The maximum levodopa induced response after the drug holiday is a result of lowered baseline tapping due to the loss of long-duration response and not due to a change in levodopa pharmacokinetics or pharmacodynamics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. M. V. Nelson, R. C. Berchou, P. A. Lewitt, D. Kareti, N. Kesaree, P. Schlick, and M. P. Galloway. Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin. Neuropharmacol. 12:91–97 (1989).

    PubMed  Google Scholar 

  2. M. Contin, R. Riva, P. Martinelli, and A. Baruzzi. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 43:367–371 (1993).

    PubMed  Google Scholar 

  3. S. Harder, H. Baas, N. Bergemann, L. Demisch, and S. Rietbrock. Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. Br. J. Clin. Pharmacol. 39:39–44 (1995).

    PubMed  Google Scholar 

  4. M. D. Muenter and G. M. Tyce. L-dopa therapy of Parkinson's disease, plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin. Proc. 46:231–239 (1971).

    PubMed  Google Scholar 

  5. C. L. Comella, J. Bohmer, and G. T. Stebbins. Sleep benefit in Parkinson's disease (Abstract). Mov. Disord. 45:A286 (1995).

    Google Scholar 

  6. L. J. Currie, J. P. Bennett, Jr., M. B. Harrison, J. M. Trugman, and G. F. Wooten. Clinical correlates of sleep benefit in Parkinson's disease. Neurology 48:1115–1117 (1997).

    PubMed  Google Scholar 

  7. M. Merello, A. Hughes, C. Colosimo, M. Hoffman, S. Starkstein, and R. Leiguarda. Sleep benefit in Parkinson's disease. Movement Disorders 12:506–508 (1997).

    PubMed  Google Scholar 

  8. J. G. Nutt, J. H. Carter, and W. R. Woodward. Long-duration response to levodopa. Neurology 45:1613–1616 (1995).

    PubMed  Google Scholar 

  9. J. G. Nutt, J. H. Carter, L. Van Houten, and W. R. Woodward. Short-and longduration responses to levodopa during the first year of levodopa therapy. Ann. Neurol. 42:349–355 (1997).

    PubMed  Google Scholar 

  10. D. E. Bateman, K. Levett, and C. D. Marsden. Sleep benefit in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67:384–385 (1999).

    PubMed  Google Scholar 

  11. J. G. Nutt, W. R. Woodward, J. H. Carter, and S. T. Gancher. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to On-Off phenomenon. Arch. Neurol. 49:1123–1130 (1992).

    PubMed  Google Scholar 

  12. J. G. Nutt, J. H. Carter, and W. R. Woodward. Effect of brief levodopa holidays on the short-duration response to levodopa. Evidence for tolerance to the antiparkinsonian effects. Neurology 44:1617–1622 (1994).

    PubMed  Google Scholar 

  13. W. R. Gibb and A. J. Lees. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51:745–752 (1988).

    PubMed  Google Scholar 

  14. A. J. Hughes, Y. Ben-Shlomo, S. E. Daniel, and A. J. Lees. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42:1142–1146 (1992).

    PubMed  Google Scholar 

  15. D. J. Gelb, E. Oliver, and S. Gilman. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56:33–39 (1999).

    Article  PubMed  Google Scholar 

  16. J. G. Nutt, W. R. Woodward, J. P. Hammerstad, J. H. Carter, and J. L. Anderson. The ''On-Off'' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J. Med. 310:483–488 (1984).

    PubMed  Google Scholar 

  17. S. T. Gancher, J. G. Nutt, and W. R. Woodward. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients. Neurology 37:940–944 (1987).

    PubMed  Google Scholar 

  18. N. H. G. Holford. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329–332 (1996).

    PubMed  Google Scholar 

  19. J. G. Wagner. Linear Compartment Models. In: Fundamentals of Clinical Pharmacokinetics. 1st ed. Hamilton: Drug Intelligence Publications, INC (1975). pp. 57–128.

    Google Scholar 

  20. N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6:429–453 (1981).

    PubMed  Google Scholar 

  21. N. H. G. Holford. MK Model, a Quantitative Modeling System for Pharmacologists. In. 5th ed.Cambridge, MA: Biosoft (1994).

    Google Scholar 

  22. G. A. F. Seber and C. J. Wild. Statistical Inference. In: Nonlinear Regression. New York: Wiley Interscience (1989), pp. 191–269.

    Google Scholar 

  23. G. Schwarz. Estimating the dimension of a model. Ann. Stat. 6:649–657 (1978).

    Google Scholar 

  24. S. Harder and H. Baas. Concentration-response relationship of levodopa in patients with different stages of Parkinson's disease. Clin. Pharmacol. Ther. 64:183–191 (1998).

    PubMed  Google Scholar 

  25. Z. Elkoshi. Concentration-effect relationship following levodopa/carbidopa administration to ''On-Off'' parkinsonian patients. Clin. Neuropharmacol. 17:147–164 (1994).

    Google Scholar 

  26. 26. R. A. Hauser and N. H. G. Holford. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 17:961–968 (2002).

    Article  PubMed  Google Scholar 

  27. J. G. Nutt, W. R. Woodward, and J. L. Anderson. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa. The mechanism of action in the treatment of parkinsonism. Ann. Neurol. 18:537–543 (1985).

    PubMed  Google Scholar 

  28. 28. R. J. Hardie, S. L. Malcolm, A. J. Lees, G. M. Stern, and J. G. Allen. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br. J. Clin. Pharmacol. 22:429–436 (1986).

    PubMed  Google Scholar 

  29. G. Fabbrini, J. Juncos, M. M. Mouradian, C. Serrati, and T. N. Chase. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann. Neurol. 21:370–376(1987).

    PubMed  Google Scholar 

  30. M. Contin, R. Riva, P. Matinelli, and A. Baruzzi. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov. Disord. 7:244–248 (1992).

    PubMed  Google Scholar 

  31. E. J. Triggs, B. G. Charles, M. Contin, P. Martinelli, P. Cortelli, R. Riva, F. Albani, and A. Baruzzi. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur. J. Clin. Pharmacol. 51:59–67 (1996).

    Article  PubMed  Google Scholar 

  32. M. Contin, R. Riva, P. Martinelli, P. Cortelli, F. Albani, and A. Baruzzi. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 44:1287–1292 (1994).

    PubMed  Google Scholar 

  33. J. G. Nutt and N. H. G. Holford. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol. 39:561–573 (1996).

    PubMed  Google Scholar 

  34. R. D. Sweet, J. E. Lee, H. E. Spiegel, and F. McDowell. Enhanced response to low dose of levodopa after withdrawal from chronic treatment. Neurology 22:520–525 (1972).

    PubMed  Google Scholar 

  35. L. K. Direnfeld, R. G. Feldman, M. P. Alezander, and M. Kelly-Hayes. Is L-dopa drug holiday useful? Neurology 30:785–788 (1980).

    PubMed  Google Scholar 

  36. W. J. Weiner, W. C. Koller, S. Perlik, P. A. Nausieda, and H. L. Klawans. Drug holiday and management of Parkinson's disease. Neurology 30:1257–1261 (1980).

    PubMed  Google Scholar 

  37. C. G. Goetz, C. M. Tanner, and P. A. Nausieda. Weekly drug holiday in Parkinson's disease. Neurology 31:1460–1462 (1981).

    PubMed  Google Scholar 

  38. G. P. Sechi, F. Tanda, and R. Mutani. Fatal hyperpyrexia after withdrawal of levodopa. Neurology. 34:249–251 (1984).

    PubMed  Google Scholar 

  39. R. Mayeux, Y. Stern, K. Mulvey, and L. Cote. Reappraisal of temporary levodopa withdrawal (''Drug Holiday'') in Parkinson's disease. New England J. Medicine 313:724–728 (1985).

    Google Scholar 

  40. L. A. Wade and R. Katzman. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood brain barrier. Life Sci. 17:131–136 (1975).

    Article  PubMed  Google Scholar 

  41. M. M. Mouradian, J. L. Juncos, G. Fabbrini, J. Schlegel, J. J. Bartko, and T. N. Chase. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann. Neurol. 24:372–378 (1988).

    PubMed  Google Scholar 

  42. R. de la Fuente-Fernandez, T. J. Ruth, V. Sossi, M. Schulzer, D. B. Calns, and A. J. Stoessl. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293:1164–1166 (2001).

    Article  PubMed  Google Scholar 

  43. J. A. Straus and S. von Ammon Cavanaugh. Placebo effects. Issues for clinical practice in psychiatry and medicine. Psychosomatics 37:315–326 (1996).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, P.L.S., Nutt, J.G. & Holford, N.H.G. Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease. J Pharmacokinet Pharmacodyn 31, 243–268 (2004). https://doi.org/10.1023/B:JOPA.0000039566.75368.59

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JOPA.0000039566.75368.59

Navigation